Companies Welcome Steps Towards Early Pan-EU HTA Talks
This article was originally published in Scrip
Executive Summary
Companies are welcoming pan-European health technology assessment initiatives, including those aimed at promoting parallel advice and early multi-HTA dialogues, according to a new report from Datamonitor Healthcare. Nevertheless, there are challenges ahead before such schemes become routine, it says.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.